Brenntag Acquires mcePharma to Boost Pharma Services in EMEA

Brenntag, the leading distributor of chemicals and additives worldwide, announced that it has acquired mcePharma in the Czech Republic. Brenntag's capabilities throughout the whole pharmaceutical and biopharmaceutical value chain will be strengthened by the acquisition and further investments in the mcePharma facility.

Key Insights:
• Brenntag acquires mcePharma to boost pharmaceutical value chain
• Enhances EMEA capabilities with GMP blending and OTC development
• Supports biopharma growth with specialized services and biobuffers

The  Pharma distributor expanding portfolio of capabilities and value-added services for principals and customers in the EMEA region will be enhanced by the company's current cutting-edge GMP facilities, sophisticated sampling services, and proficiency in both OTC product development and GMP powder pack-off.

“The integration of GMP blending and down-packing, along with added warehouse and office space, positions us to meet growing demand while ensuring operational excellence. It’s a powerful enhancement to our portfolio that reinforces our commitment to quality, speed, and customer-centric solutions” said Joakim Rehné, President Pharma EMEA at Brenntag.

Also Read:Minimum Import Price Policy Aims to Boost Domestic Pharma Resilience

Gust Desmedt, Global President Pharma at Brenntag Specialties, noted: “This acquisition represents a key milestone in our strategic initiatives to further expand our biopharmaceutical services on top of our offering in traditional small molecules. With the added capabilities mcePharma offers, we are confident we can serve additional customers with value added services and serve the needs of our supply partners in the rapid growing Biopharma market in EMEA and globally with specialized biobuffers.”